BioNTech CEO Ugur Sahin Sells $7.89M in Ordinary Shares via Rule 10b5-1 Plan
BioNTech SE
Subscribe to track BNTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BioNTech SE ($BNTX) — Insider Sale Insider: Sahin Ugur (Chief Executive Officer, 10% Owner) Type: Sale (Open Market / 10b5-1) Shares Sold: 76,500 Average Price: ~$103.12 Total Value: $7,889,055.30 Remaining Holdings: 781,709 shares Transaction Dates: 2026-09-03 to 2026-09-04
Comprehensive Analysis
Executive Summary
On September 8, 2026, BioNTech SE (BNTX) filed a Form 4 disclosing open-market sales by Chief Executive Officer and 10% owner Ugur Sahin. Across September 3 and September 4, 2026, Dr. Sahin sold an aggregate of 76,500 ordinary shares at a volume-weighted average price of approximately $103.12, generating gross proceeds of $7,889,055.30.
Transaction Details
- September 3, 2026: Sold 45,000 shares at an average price of $102.8496 ($4,628,232.00).
- September 4, 2026: Sold 31,500 shares at an average price of $103.5182 ($3,260,823.30).
- Post-Transaction Beneficial Ownership: 781,709 ordinary shares held directly.
Context and Trading Plan
The filing notes that the transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 3, 2026. Because these sales were conducted under an established scheduled plan, they represent planned liquidity/portfolio management rather than discretionary market timing.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.